Suppr超能文献

SCRIPT 试验:一项针对多基因风险评分的随机对照试验的研究方案,旨在为初级保健中的结直肠癌筛查提供个性化服务。

The SCRIPT trial: study protocol for a randomised controlled trial of a polygenic risk score to tailor colorectal cancer screening in primary care.

机构信息

Primary Care Cancer Research Group, Department of General Practice, Centre for Cancer Research, The University of Melbourne, Victorian Comprehensive Cancer Centre, Level 10, 305 Grattan Street, Melbourne, Victoria, 3000, Australia.

Centre for Cancer Research, University of Melbourne, Melbourne, Australia.

出版信息

Trials. 2022 Sep 27;23(1):810. doi: 10.1186/s13063-022-06734-7.

Abstract

BACKGROUND

Polygenic risk scores (PRSs) can predict the risk of colorectal cancer (CRC) and target screening more precisely than current guidelines using age and family history alone. Primary care, as a far-reaching point of healthcare and routine provider of cancer screening and risk information, may be an ideal location for their widespread implementation.

METHODS

This trial aims to determine whether the SCRIPT intervention results in more risk-appropriate CRC screening after 12 months in individuals attending general practice, compared with standard cancer risk reduction information. The SCRIPT intervention consists of a CRC PRS, tailored risk-specific screening recommendations and a risk report for participants and their GP, delivered in general practice. Patients aged between 45 and 70 inclusive, attending their GP, will be approached for participation. For those over 50, only those overdue for CRC screening will be eligible to participate. Two hundred and seventy-four participants will be randomised to the intervention or control arms, stratified by general practice, using a computer-generated allocation sequence. The primary outcome is risk-appropriate CRC screening after 12 months. For those in the intervention arm, risk-appropriate screening is defined using PRS-derived risk; for those in the control arm, it is defined using family history and national screening guidelines. Timing, type and results of the previous screening are considered in both arms. Objective health service data will capture screening behaviour. Secondary outcomes include cancer-specific worry, risk perception, predictors of CRC screening behaviour, screening intentions and health service use at 1, 6 and 12 months post-intervention delivery.

DISCUSSION

This trial aims to determine whether a PRS-derived personalised CRC risk estimate delivered in primary care increases risk-appropriate CRC screening. A future population risk-stratified CRC screening programme could incorporate risk assessment within primary care while encouraging adherence to targeted screening recommendations.

TRIAL REGISTRATION

Australian and New Zealand Clinical Trial Registry ACTRN12621000092897p. Registered on 1 February 2021.

摘要

背景

与仅使用年龄和家族史的现行指南相比,多基因风险评分 (PRS) 可更准确地预测结直肠癌 (CRC) 的风险并更有针对性地进行筛查。初级保健作为医疗保健的广泛切入点和常规的癌症筛查和风险信息提供者,可能是其广泛实施的理想场所。

方法

本试验旨在确定与标准癌症风险降低信息相比,在接受普通科医生就诊的个体中, SCRIPT 干预是否会在 12 个月后导致更合适的 CRC 筛查。 SCRIPT 干预包括 CRC PRS、针对特定风险的个性化筛查建议以及参与者及其 GP 的风险报告,在普通科医生就诊时提供。将邀请年龄在 45 至 70 岁之间(含)、在其 GP 就诊的患者参加。对于 50 岁以上的患者,只有那些 CRC 筛查逾期的患者才有资格参加。将根据普通科医生进行分层,使用计算机生成的分配序列将 274 名参与者随机分配到干预组或对照组。主要结局是 12 个月后风险适宜的 CRC 筛查。对于干预组的患者,使用 PRS 衍生的风险来定义适当的筛查;对于对照组的患者,使用家族史和国家筛查指南来定义适当的筛查。在两个组中都考虑了以前筛查的时间、类型和结果。客观的卫生服务数据将捕获筛查行为。次要结局包括癌症特异性担忧、风险感知、CRC 筛查行为的预测因素、筛查意向和干预后 1、6 和 12 个月的卫生服务使用。

讨论

本试验旨在确定在初级保健中提供基于 PRS 的个性化 CRC 风险估计是否会增加适当的 CRC 筛查。未来的人群风险分层 CRC 筛查计划可以在初级保健中纳入风险评估,同时鼓励遵循有针对性的筛查建议。

试验注册

澳大利亚和新西兰临床试验注册中心 ACTRN12621000092897p。于 2021 年 2 月 1 日注册。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d1d0/9513879/0d2cf6480dae/13063_2022_6734_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验